Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs
Bullboard Posts
User Avatar Image
(5)
•••
Comment by roadking08on May 03, 2018 8:50pm
104 Views
Post# 27980269

RE:RE:RE:RE:RE:RE:RE:RE:RE:Ask lot!!

RE:RE:RE:RE:RE:RE:RE:RE:RE:Ask lot!!Regardless, thanks for your support at .65,
actually many thanks! Me, family members and friends that have bought very high and seen this go down from the 2$ share since  vaccinex deal in 2016 also thank you. 
Just one simple question for all?......actually very simple, since most here I think will definitely blame Tailwinds if ever we do go down in the fifty cent range from .65, who is to blame from 2$ to 0.65? even better, how did we get to two bucks in the first place?

I am all ears, and while I’m at it, I thought 90% of Tailwinds write up was very positive for all our future wallets and don’t understand why shares should not be bought now, I think we can agree 110% that a deal or financing is very very near! 

Not whining OttawaPeter, just saying....and some asking....but definitely not whining......
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities